Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial

IMPORTANCE: Adjuvant therapy is an important and effective treatment for breast cancer. However, there is a lack of head-to-head clinical trials comparing the regimens epirubicin plus paclitaxel (EP) vs epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in breast cancer. OBJECTIVE: To eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Peng, Kang, Yikun, Ma, Fei, Fan, Ying, Wang, Jiayu, Wang, Xue, Yue, Jian, Luo, Yang, Zhang, Pin, Li, Qing, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958529/
https://www.ncbi.nlm.nih.gov/pubmed/36826820
http://dx.doi.org/10.1001/jamanetworkopen.2023.0122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958529/
https://www.ncbi.nlm.nih.gov/pubmed/36826820
http://dx.doi.org/10.1001/jamanetworkopen.2023.0122

Ejemplares similares